Drug maker lays off 300 jobs in the US


Drugmaker Amgen said Monday it was laying off about 300 U.S. employees, about 1.2 percent of its workforce. It cites recent organizational changes in the company’s commercial team.

The company had approximately 24,200 employees in more than 50 countries as of December 31, 2021, according to its most recent annual regulatory filing with the U.S. Securities and Exchange Commission.

Big tech companies and Wall Street giants have led to mass layoffs across American companies in recent weeks. Amgen’s move to cut workforce illustrates how rapid interest rate hikes and a spike in post-pandemic demand are beginning to impact the healthcare sector.

About Amgen

According to Amgen’s website, the company is committed to unlocking the biological potential for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapies. This approach begins with the use of tools such as advanced human genetics. To unravel the complexity of disease and understand the fundamentals of human biology.

Amgen focuses on highly unmet medical needs. and leverage its expertise to seek solutions that improve health outcomes and dramatically improve people’s lives. Amgen has been a biotechnology pioneer since 1980 and has grown to become one of the world’s leading independent biotechnology companies. Reach millions of patients worldwide. and is developing a potential drug pipeline for severity.

Amgen is one of 30 companies with the Dow Jones Industrial Average and is part of the Nasdaq-100 Index. “World’s Best Employers” by Forbes and one of “America’s 100 Most Sustainable Companies” by Barron’s.


Leave A Reply

Your email address will not be published.